GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Price-to-Free-Cash-Flow
中文

DexCom (DexCom) Price-to-Free-Cash-Flow

: 111.30 (As of Today)
View and export this data going back to 2005. Start your Free Trial

As of today (2024-04-24), DexCom's share price is $134.01. DexCom's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.20. Hence, DexCom's Price-to-Free-Cash-Flow Ratio for today is 111.30.

The historical rank and industry rank for DexCom's Price-to-Free-Cash-Flow or its related term are showing as below:

DXCM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 65.01   Med: 253.3   Max: 21282.5
Current: 111.28

During the past 13 years, DexCom's highest Price-to-Free-Cash-Flow Ratio was 21282.50. The lowest was 65.01. And the median was 253.30.

DXCM's Price-to-Free-Cash-Flow is ranked worse than
86.98% of 338 companies
in the Medical Devices & Instruments industry
Industry Median: 31.755 vs DXCM: 111.28

DexCom's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.19. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $1.20.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of DexCom was 68.70% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 19.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 34.60% per year.

During the past 13 years, DexCom's highest 3-Year average Free Cash Flow per Share Growth Rate was 614.00% per year. The lowest was -8.00% per year. And the median was 25.10% per year.


DexCom Price-to-Free-Cash-Flow Historical Data

The historical data trend for DexCom's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.23 130.37 1,082.56 158.82 103.15

DexCom Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 158.82 118.31 117.58 79.61 103.15

Competitive Comparison

For the Medical Devices subindustry, DexCom's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where DexCom's Price-to-Free-Cash-Flow falls into.



DexCom Price-to-Free-Cash-Flow Calculation

DexCom's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=134.01/1.204
=111.30

DexCom's Share Price of today is $134.01.
DexCom's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

DexCom  (NAS:DXCM) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


DexCom Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of DexCom's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q3 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024